Sales of MS and eczema drugs could top $4bn by 2022
Company nabs maintenance therapy use, but problems on breast cancer trial.
Algorithm accurately detects depression from brain scans in 75% of cases.
Tangible improvements can be seen in clinical outcomes and treatment satisfaction if patients are involved.
Technical officer hinted that the firm has hit obstacles to its ambitious projects.
New cost-capping and delaying measures will further restrict access to new medicines say pharma and patient groups.
02/11/2016November 1, 2016
‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.